SuperworthDamora Therapeutics EPS DMRA
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$139.09
- Latest quarter, Q2 FY26
- −$0.39
- Fiscal year 2025
- −$142.60
Damora Therapeutics' earnings per share was −$139.09 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.39.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$142.60 | n/a |
| FY2024 | −$18.49 | n/a |
| FY2023 | −$36.47 | n/a |
| FY2022 | −$60.75 | n/a |
| FY2021 | −$51.25 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.39 | n/a | −$139.09 | |
| Q1 FY26 | −$0.62 | n/a | −$141.30 | |
| Q4 FY25 | −$135.72 | n/a | −$142.60 | |
| Q3 FY25 | −$2.36 | n/a | −$12.01 | |
| Q2 FY25 | −$2.60 | n/a | −$13.04 | |
| Q1 FY25 | −$1.92 | n/a | −$15.36 | |
| Q4 FY24 | −$5.13 | n/a | −$18.49 | |
| Q3 FY24 | −$3.39 | n/a | −$19.33 | |
| Q2 FY24 | −$4.92 | n/a | −$23.44 | |
| Q1 FY24 | −$5.05 | n/a | −$28.77 | |
| Q4 FY23 | −$5.97 | n/a | −$36.47 | |
| Q3 FY23 | −$7.50 | n/a | −$44.25 |
Against its peers
Companies in Drug Manufacturers - General nearest Damora Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DMRADamora Therapeutics | −$139.09 | |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| ABUSArbutus Biopharma | $0.78 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Damora Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.